Skip to search formSkip to main contentSkip to account menu

empagliflozin

Known as: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene 
National Institutes of Health

Related topics

Related topics

14 relations

Narrower (3)

BI 10773GlyxambiJardiance

Broader (3)

Benzhydryl CompoundsGlucosidesHypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors [MoA]empagliflozin / Linagliptinempagliflozin / Metforminempagliflozin 10 MG / Linagliptin 5 MG Oral Tablet [Glyxambi]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
2018
2018
SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
Review
2017
Review
2017
Cardiovascular disease leads to a new algorithm for diabetes treatment.
2017
2017
Mean Centering Method for determination of Empagliflozin and Metformin
Introduction of computer-assisted analysis to pharmaceutical products is considered a significant approach. A new method was… 
2016
2016
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
2016
2016
DNA-Repair Gene Mutations in Metastatic Prostate Cancer.
TO THE EDITOR: The study by Pritchard et al. (Aug. 4 issue)1 has major implications for translational science, and it provides… 
Review
2016
Review
2016
Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
2016
2016
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
Aims/hypothesisSodium glucose co-transporter 2 (SGLT2) inhibitors lower glycaemia by inducing glycosuria, but raise endogenous… 
2016
2016
Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
More than 10 million Canadians are currently living with diabetes.[1][1] Of those, 90% have type 2 diabetes mellitus (T2DM).[1][1… 
2014
2014
Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13.
Empagliflozin, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)